Biologics/Immunotherapy News

WASHINGTON — Male and female patients experienced similar improvements in their severe, uncontrolled asthma with tezepelumab over a 52-week period, according to data presented at the American Thoracic Society International Conference.

Treatment with benralizumab induced histological remission, defined as an absence of tissue eosinophilia, among patients with eosinophilic gastritis, according to a study published in The Lancet Gastroenterology & Hepatology.

WASHINGTON — A debate at the American Thoracic Society International Conference changed some minds about whether providers could or should combine and overlap biologic treatments to treat severe asthma.

Healio compiled the most-read news in allergy, asthma and immunology posted in May.

The FDA approved avapritinib for treatment of adults with indolent systemic mastocytosis, according to a press release from the agent’s manufacturer.

WASHINGTON — Patients with asthma experienced fast and substantial reductions in fractional exhaled nitric oxide with the SAR443765 bifunctional NANOBODY molecule, which blocks thymic stromal lymphopoietin and IL-13, according to a study.

WASHINGTON — Tezepelumab reduced annualized asthma exacerbation rates compared with placebo among patients with severe, uncontrolled asthma regardless of prior omalizumab use, according to study results.

Epicutaneous immunotherapy was superior to placebo in desensitizing toddlers to peanuts and in increasing the dose of peanuts that trigger allergic symptoms, according to a study published in The New England Journal of Medicine.

Adolescents and adults experienced sustained improvements in eosinophilic esophagitis outcomes with dupilumab for up to 52 weeks, according to research presented at Digestive Disease Week 2023 in Chicago.

Single-food oral immunotherapy and simultaneous OITs for multiple foods both were safe and feasible via established protocols, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.